Gadolinuma Bağlı Akut Böbrek Hasarı: Bir Olgu Sunumu

Yıl 2019, Cilt: 9 Sayı: 4, 706 - 709, 16.12.2019

Hamad Dheir , Serap Üngan Ahmed Bilal Genç Necattin Firat , Selcuk Yaylacı , Savaş Sipahi

https://doi.org/10.31832/smj.596029

Öz

Son zamanlarda, manyetik rezonans
görüntüleme (MRG) incelemeleri için kullanılan gadolinyum bazlı kontrast maddenin
(Gd-KM) akut böbrek hasarını (AKH) indüklediği bildirilmeye başlanmıştır.
Hiçbir risk faktörü olmayan, batın MRG sonrası AKH gelişen hastayı bildirmek
istedik. 

Anahtar Kelimeler

gadolinum, akut böbrek hasarı

Kaynakça

• 1. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, et al. Nephrogenic Systemic Fibrosis: Suspected Causative Role of Gadodiamide Used for Contrast-Enhanced Magnetic Resonance Imaging. J Am Soc Nephrol. 2006;17:2359–62. doi:10.1681/ASN.2006060601.2. Chien C-C, Wang H-Y, Wang J-J, Kan W-C, Chien T-W, Lin C-Y, et al. Risk of Acute Kidney Injury after Exposure to Gadolinium-Based Contrast in Patients with Renal Impairment. Ren Fail. 2011;33:758–64. doi:10.3109/0886022X.2011.599911.3. Takahashi EA, Kallmes DF, Mara KC, Harmsen WS, Misra S. Nephrotoxicity of gadolinium-based contrast in the setting of renal artery intervention: retrospective analysis with 10-year follow-up. Diagn Interv Radiol. 2018;24:378–84. doi:10.5152/dir.2018.18172.4. Schieda N, Maralani PJ, Hurrell C, Tsampalieros AK, Hiremath S. Updated Clinical Practice Guideline on Use of Gadolinium-Based Contrast Agents in Kidney Disease Issued by the Canadian Association of Radiologists. Can Assoc Radiol J. 2019. doi:10.1016/j.carj.2019.04.001.5. Perazella MA. Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis. Curr Drug Saf. 2008;3:67–75. http://www.ncbi.nlm.nih.gov/pubmed/18690983. Accessed 21 Jul 2019.6. Fujisaki K, Ono-Fujisaki A, Kura-Nakamura N, Komune N, Hirakawa N, Tsuruya K, et al. Rapid deterioration of renal insufficiency after magnetic resonance imaging with gadolinium-based contrast agent. Clin Nephrol. 2011;75:251–4. doi:10.5414/cnp75251.7. Khwaja A. KDIGO Clinical Practice Guidelines for Acute Kidney Injury. Nephron. 2012;120:c179–84. doi:10.1159/000339789.8. Tervahartiala P. Contrast media-induced renal tubular vacuolization after dehydration. A light and electron microscopic study in rats. Invest Radiol. 1992;27:114–8. http://www.ncbi.nlm.nih.gov/pubmed/1601601. Accessed 21 Jul 2019.9. Tumlin J, Stacul F, Adam A, Becker CR, Davidson C, Lameire N, et al. Pathophysiology of contrast-induced nephropathy. Am J Cardiol. 2006;98:14K-20K. doi:10.1016/j.amjcard.2006.01.020.10. Akgun H, Gonlusen G, Cartwright J, Suki WN, Truong LD. Are gadolinium-based contrast media nephrotoxic? A renal biopsy study. Arch Pathol Lab Med. 2006;130:1354–7. doi:10.1043/1543-2165(2006)130[1354:AGCMNA]2.0.CO;2.11. Boyden TF, Gurm HS. Does gadolinium-based angiography protect against contrast-induced nephropathy?: a systematic review of the literature. Catheter Cardiovasc Interv. 2008;71:687–93. doi:10.1002/ccd.21459.12. Haustein J, Laniado M, Niendorf HP, Louton T, Beck W, Planitzer J, et al. Triple-dose versus standard-dose gadopentetate dimeglumine: a randomized study in 199 patients. Radiology. 1993;186:855–60. doi:10.1148/radiology.186.3.8430199.13. Prince MR, Arnoldus C, Frisoli JK. Nephrotoxicity of high-dose gadolinium compared with iodinated contrast. J Magn Reson Imaging. 6:162–6. http://www.ncbi.nlm.nih.gov/pubmed/8851422. Accessed 21 Jul 2019.14. Sam AD, Morasch MD, Collins J, Song G, Chen R, Pereles FS. Safety of gadolinium contrast angiography in patients with chronic renal insufficiency. J Vasc Surg. 2003;38:313–8. http://www.ncbi.nlm.nih.gov/pubmed/12891113. Accessed 21 Jul 2019.